Targeting Akt by SC66 triggers GSK-3 β mediated apoptosis in colon cancer therapy

Colon cancer is one of the three common malignant tumors, with lower 5 years survival rate. Akt is an important therapeutic target, while SC66 is a novel allosteric AKT inhibitor, which enhances the therapeuti...

Source: Cancer Cell International - May 9, 2019 Category: Cancer & Oncology Authors: Yeying Liu, Yuan Huang, Jie Ding, Nannan Liu, Shuang Peng, Jiangang Wang, Feng Wang and Yingjie Zhang Tags: Primary research Source Type: research